Clinical Trial Update: Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) [Phase 3]

View source ↗

Summary

Phase 3 open-label study of LMTM in Alzheimer's disease and behavioral variant frontotemporal dementia has been terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Behavioral Variant Frontotemporal Dementia

Drugs mentioned

• Leuco-methylthioninium bis(Hydromethanesulfonate) (leuco-methylthioninium bis(hydromethanesulfonate))

Snippet

Sponsor: TauRx Therapeutics Ltd | Conditions: Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia | Phase 3 | Status: TERMINATED | Results posted: 2020-06-02